Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. (Nasdaq: ALT) generates a steady flow of news as a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver, metabolic and cardiometabolic diseases. Most company updates center on its lead investigational medicine, pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), alcohol-associated liver disease (ALD) and obesity.
News coverage of ALT frequently highlights clinical trial milestones. Altimmune issues detailed press releases on the IMPACT Phase 2b trial in MASH, including 24-week and 48-week topline data, changes in non-invasive tests of fibrosis and hepatic inflammation, and AI-based digital pathology analyses of liver biopsies. Additional updates describe progress in the RECLAIM Phase 2 trial in AUD and the RESTORE Phase 2 trial in ALD, including enrollment status and expected timelines for topline results.
Investors and followers of ALT stock also see regulatory and scientific news, such as Fast Track designations for pemvidutide in MASH and AUD, Breakthrough Therapy Designation for MASH, and publication of IMPACT trial data in peer-reviewed journals. Presentations at major medical meetings, including late-breaking oral and poster sessions at The Liver Meeting hosted by the American Association for the Study of Liver Diseases (AASLD), are common subjects of company announcements.
Altimmune’s news flow further includes corporate and financial updates. These range from quarterly financial results and business updates to CEO succession plans, executive appointments, term loan amendments and at-the-market equity offering arrangements disclosed in SEC filings and companion press releases. For anyone tracking ALT, this news page brings together clinical, regulatory, scientific and corporate developments in one place, making it easier to follow how Altimmune’s programs and capital strategy evolve over time.
Altimmune (NASDAQ: ALT) has announced its Q4 and full year 2024 financial results, highlighting significant progress in its pemvidutide development program. The company reports cash reserves of $131.9 million as of December 31, 2024.
Key developments include:
- Top-line data from Phase 2b IMPACT trial in MASH expected in Q2 2025
- FDA clearance received for two additional pemvidutide indications
- Phase 2 trials for new indications to commence mid-2025
Financial highlights for Q4 2024:
- R&D expenses: $19.8 million
- G&A expenses: $5.1 million
- Net loss: $23.2 million ($0.33 per share)
The company strengthened its Board with two pharmaceutical industry veterans and plans to hold a virtual R&D Day on March 13, 2025.
Altimmune (Nasdaq: ALT) has appointed Teri Lawver and Jerry Durso to its Board of Directors as the company advances into late-stage clinical development for pemvidutide and prepares for transition to a pre-commercial organization.
Lawver brings nearly 30 years of healthcare experience, most recently serving as Chief Commercial Officer at Dexcom where she led the launch of the industry's first over-the-counter glucose biosensor. Previously, she spent 20 years at Johnson & Johnson in senior leadership roles, including global commercial responsibility for Janssen's $16 billion immunology portfolio.
Durso has over 30 years of leadership experience, most recently as CEO of Intercept Pharmaceuticals where he built a successful rare liver disease franchise and led the company through its acquisition by Alfasigma. He previously spent over 20 years at Sanofi in various senior positions.
Both executives will help guide Altimmune's strategic vision to develop and commercialize pemvidutide, which has shown promising effects on liver defatting, weight loss, and serum lipid improvements.
Altimmune (Nasdaq: ALT) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The clinical-stage biopharmaceutical company will host a conference call at 8:30 am E.T. on the same day, during which management will discuss financial results and provide a business update.
The conference call will be accessible through a webcast on Altimmune's Investor Relations website. Interested participants can register online to receive dial-in numbers and a unique PIN for call access. A replay of the call will be available on the company's Investor Relations website for up to three months following the event.
Altimmune (Nasdaq: ALT), a clinical-stage biopharmaceutical company, has announced its upcoming participation in the Guggenheim SMID Cap Biotech Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, February 5, 2025, at 9:30 a.m. EST.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation represents an opportunity for investors and stakeholders to gain insights into the company's developments and strategic direction.
Altimmune (Nasdaq: ALT) announced its addition to the Nasdaq Biotechnology Index (NBI) effective December 23, 2024. The company's CEO, Vipin K. Garg, highlighted this as an important recognition following a year of major progress. Looking ahead to 2025, the company anticipates significant milestones, including topline data from the Phase 2b IMPACT trial of pemvidutide in MASH expected in Q2. The NBI, established in 1993, tracks Nasdaq-listed biotechnology and pharmaceutical securities that meet specific eligibility criteria including market capitalization, trading volume, and seasoning requirements.
Altimmune (Nasdaq: ALT) announced that their Chief Medical Officer, Dr. Scott Harris, will present at the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C. The presentation will focus on body composition data from the Phase 2 MOMENTUM trial of pemvidutide in obesity treatment. Dr. Harris will participate in a panel discussion titled 'Muscle Wasting in Weight Loss Therapy' during the session 'Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory Issues' on Friday, December 6, 2024, at 9:30 am ET.
Altimmune (Nasdaq: ALT) has announced its participation in two upcoming investor conferences. The company's management team will be present at the Annual Evercore HealthCONx Conference in Coral Gables, FL on December 3, 2024, featuring a fireside chat at 10:50 a.m. ET, and the Piper Sandler Annual Healthcare Conference in New York, NY on December 4, 2024, with a fireside chat scheduled for 3:30 p.m. ET. Both sessions will be available via webcast through the Events section of Altimmune's website. The team will also be available for one-on-one meetings during these events.
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®. The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascular health markers. In the trial of 94 subjects, pemvidutide reduced liver fat content by up to 68.5%, total cholesterol by 12.2%, and triglycerides by 44.6% after 12 weeks. The company is currently conducting the Phase 2b IMPACT trial in MASH patients, with results expected in Q2 2025.
Altimmune (ALT) announced key developments in Q3 2024, including completion of enrollment in the Phase 2b IMPACT trial of pemvidutide for MASH, with top-line data expected in Q2 2025. The company successfully completed its End-of-Phase 2 FDA meeting for pemvidutide's obesity program, planning four Phase 3 trials. At EASD, they presented promising data showing pemvidutide's lean mass preservation and visceral fat reduction. The company plans to submit INDs for up to three additional pemvidutide indications starting Q4 2024.
Financial results showed $139.4 million in cash and investments, R&D expenses of $19.8 million, and a net loss of $22.8 million ($0.32 per share) for Q3 2024.
Altimmune (Nasdaq: ALT) announced equity awards granted to incoming Chief Financial Officer Gregory Weaver, effective November 11, 2024. The compensation package includes options to purchase 225,000 shares of common stock and 75,000 restricted stock units (RSUs). Based on November 8 closing price, approximately 172,920 options would be issued as inducement awards, with the remainder as incentive stock options. The options and RSUs will vest over four years, with 25% vesting after the first year and the remainder vesting gradually, subject to continued employment.